Britannin (20 mg/kg, i.p., once daily for 3 consecutive days) ameliorates lung injury and systemic infection in Lipopolysaccharides (LPS) (HY-D1056) -induced acute lung injury mouse model in an NLRP3-dependent manner[4].
Britannin (20 mg/kg, i.p., once every other day, for a total of 3 injections) relieves gouty arthritis in Monosodium urate (HY-B2130A) -induced gouty arthritis mouse model by inhibiting NLRP3 activation[4].
| Animal Model: | Monosodium urate (HY-B2130A) -induced gouty arthritis mouse model, Lipopolysaccharides (LPS) (HY-D1056) -induced acute lung injury mouse model[4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), inject for three consecutive days (acute lung injury mouse model) or once every other day, for a total of 3 injections (Monosodium urate (HY-B2130A) -induced gouty arthritis mouse model) |
| Result: | Significantly suppressed the changes in footpad joint size, alleviated the migration of inflammatory cells in Monosodium urate (HY-B2130A) -induced gouty arthritis mouse model and nhibited the secretion of IL-1β and the activation of Caspase-1, demonstrating that
Britannin prevented gouty arthritis through anti-inflammatory effects.
Suppressed pulmonary edema, breakdown of the pneumatic blood barrier, and cell infiltration in lung tissues and pathological injury and inflammatory cell infiltration in lung tissues, were ameliorated by Britannin treatment.
|